Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Digoxin

FDA-approved product (injectable, injection), marketed as Digoxin, Digoxin Pediatric, Lanoxicaps and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Digoxin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrial fibrillation
  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Digitalis glycosides
FDA pharmacologic class
Cardiac Glycoside FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Digoxin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Digoxin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Digoxin Medulloblastoma Study

    NCT06701812 · start 2026-01-15

    Registered record
    Registry ID
    NCT06701812
    Conditions
    Medulloblastoma; Medulloblastoma, Non-WNT/Non-SHH
    Interventions
    Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-15
    Completion
    2027-02
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedulloblastoma; Medulloblastoma, Non-WNT/Non-SHH
    InterventionDigoxin
    PhasePhase 2
    Registry statusRecruiting

  • Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

    NCT07223671 · start 2025-12-31

    Registered record
    Registry ID
    NCT07223671
    Conditions
    Healthy Volunteers
    Interventions
    Repotrectinib; Metformin; Digoxin; Rosuvastatin; Bupropion; Flurbiprofen; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-12-31
    Completion
    2026-03-19
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionRepotrectinib; Metformin; Digoxin; Rosuvastatin +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body

    NCT07215260 · start 2025-11-05

    Registered record
    Registry ID
    NCT07215260
    Conditions
    Healthy
    Interventions
    BI 3000202; Rosuvastatin; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-11-05
    Completion
    2025-12-18
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 3000202; Rosuvastatin; Digoxin
    PhasePhase 1
    Registry statusCompleted

  • Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

    NCT07025850 · start 2025-08-01

    Registered record
    Registry ID
    NCT07025850
    Conditions
    Colorectal Carcinoma
    Interventions
    Digoxin; Fuquinitinib; Tislelizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-08-01
    Completion
    2027-05-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Carcinoma
    InterventionDigoxin; Fuquinitinib; Tislelizumab
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Digoxin In NASH (CODIN)

    NCT06588699 · start 2025-06-05

    Registered record
    Registry ID
    NCT06588699
    Conditions
    NASH; NAFLD; MASH - Metabolic Dysfunction-Associated Steatohepatitis; Mash; MASH With Fibrosis; MASLD; Fatty Liver Disease; Fatty Liver Disease, Nonalcoholic
    Interventions
    Digoxin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-05
    Completion
    2029-01
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNASH; NAFLD; MASH - Metabolic Dysfunction-Associated Steatohepatitis; Mash +4 more
    InterventionDigoxin; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

    NCT06793943 · start 2025-01-23

    Registered record
    Registry ID
    NCT06793943
    Conditions
    Healthy Volunteers
    Interventions
    Zasocitinib; COC; Metformin; Digoxin; Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-01-23
    Completion
    2025-03-30
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionZasocitinib; COC; Metformin; Digoxin +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

    NCT06717269 · start 2024-11-30

    Registered record
    Registry ID
    NCT06717269
    Conditions
    Healthy Volunteer
    Interventions
    NX-5948; Esomeprazole; Placebo; Famotidine; Midazolam; Digoxin; Rosuvastatin; Quinidine; NX-5948
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-11-30
    Completion
    2026-05-01
    Enrolment
    223

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionNX-5948; Esomeprazole; Placebo; Famotidine +5 more
    PhasePhase 1
    Registry statusCompleted

  • PK/PD of Digoxin in Infants With SVHD

    NCT06613477 · start 2024-10-10

    Registered record
    Registry ID
    NCT06613477
    Conditions
    Single-ventricle; Infant Conditions; Infant, Newborn, Diseases; Infant, Premature, Diseases
    Interventions
    PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2024-10-10
    Completion
    2026-04-21
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSingle-ventricle; Infant Conditions; Infant, Newborn, Diseases; Infant, Premature, Diseases
    InterventionPK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

    NCT07307131 · start 2024-09-01

    Registered record
    Registry ID
    NCT07307131
    Conditions
    Cutaneous Warts; Human Papilloma Virus (HPV)
    Interventions
    Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml); Intralesional polidocanol 2%
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-09-01
    Completion
    2025-09-30
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Warts; Human Papilloma Virus (HPV)
    InterventionIntralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml); Intralesional polidocanol 2%
    PhasePhase 2
    Registry statusCompleted

  • A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

    NCT06416800 · start 2024-06-19

    Registered record
    Registry ID
    NCT06416800
    Conditions
    Healthy Participants
    Interventions
    Digoxin; Rosuvastatin; Metformin; Povorcitinib; Probenecid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-06-19
    Completion
    2025-01-15
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionDigoxin; Rosuvastatin; Metformin; Povorcitinib +1 more
    PhasePhase 1
    Registry statusCompleted

  • ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

    NCT06293742 · start 2024-02-08

    Registered record
    Registry ID
    NCT06293742
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    ECC5004; Midazolam; Rosuvastatin; Digoxin; Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-02-08
    Completion
    2024-04-15
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionECC5004; Midazolam; Rosuvastatin; Digoxin +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

    NCT06105255 · start 2023-05-24

    Registered record
    Registry ID
    NCT06105255
    Conditions
    Healthy Male
    Interventions
    D-1553
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-05-24
    Completion
    2024-02-02
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male
    InterventionD-1553
    PhasePhase 1
    Registry statusCompleted

  • Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

    NCT05657613 · start 2023-01-03

    Registered record
    Registry ID
    NCT05657613
    Conditions
    Drug Interactions
    Interventions
    CYP450 Cocktail and Transporter Substrates with Pacritinib; Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib; Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-01-03
    Completion
    2023-06-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interactions
    InterventionCYP450 Cocktail and Transporter Substrates with Pacritinib; Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib; Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

    NCT05395117 · start 2022-06-30

    Registered record
    Registry ID
    NCT05395117
    Conditions
    Healthy Participants
    Interventions
    AZD5462; Midazolam; Rosuvastatin; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-30
    Completion
    2022-09-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAZD5462; Midazolam; Rosuvastatin; Digoxin
    PhasePhase 1
    Registry statusCompleted

  • Digoxin In Treatment of Alcohol Associated Hepatitis

    NCT05014087 · start 2021-10-08

    Registered record
    Registry ID
    NCT05014087
    Conditions
    Acute Alcoholic Hepatitis; Chemical and Drug Induced Liver Injury; Alcohol-Induced Disorders; Steatohepatitis Caused by Ingestible Alcohol
    Interventions
    Intravenous digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-10-08
    Completion
    2025-09-12
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Alcoholic Hepatitis; Chemical and Drug Induced Liver Injury; Alcohol-Induced Disorders; Steatohepatitis Caused by Ingestible Alcohol
    InterventionIntravenous digoxin
    PhasePhase 2
    Registry statusTerminated